(BPT) - As people age, it's sometimes easy to attribute body aches to daily routines or external factors. However, stiffness and pain in a person's shoulders, neck or hips could signal something more serious, like polymyalgia rheumatica (PMR).
PMR is a type of inflammatory rheumatic disease that impacts around 1 in 2,000 people aged 50 and above, with women more likely to be affected, and the risk of developing it increases with age.1-2 Many people with PMR report worsening symptoms in the morning or after periods of inactivity, particularly when performing everyday tasks like lifting objects or standing up. Recognizing the early signs of PMR and talking to a doctor are important to figuring out a treatment plan to help manage symptoms.
Dr. Grace Wright, MD, PhD, president of the Association of Women in Rheumatology and a practicing rheumatologist in New York City, explains how doctors can guide their patients through their diagnosis and treatment experience. She explains that by encouraging open communication between patients and doctors, "patients can feel empowered and informed throughout their care journey."
Consult Your Doctor Early: Addressing PMR Symptoms for Timely Diagnosis and Treatment
Effective Communication: Differentiating PMR Symptoms for Accurate Diagnosis
Managing PMR: Understanding Treatment Options and the Importance of Monitoring Health Conditions
Resources and Support to Stay Informed
Another Option for Treating PMR
Important Safety Information
KEVZARA® (sarilumab) can cause serious side effects including:
These are not all the possible side effects of KEVZARA. Tell your doctor about any side effect that bothers you or does not go away. You are encouraged to report side effects of prescription drugs to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.
To learn more, talk about KEVZARA with your healthcare provider or pharmacist. The FDA-approved Medication Guide and Prescribing Information can be found at www.KEVZARA.com or by calling 1-844- KEVZARA.
Please click here to see full Prescribing Information including risk of SERIOUS SIDE EFFECTS and Medication Guide.
References
MAT-US-2410843-v1.0-11/2024